Haemonetics Co. (NYSE:HAE) Receives Average Rating of “Moderate Buy” from Analysts

Haemonetics Co. (NYSE:HAE) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $101.22.

Several equities research analysts have commented on the company. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Needham & Company LLC lowered their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Finally, Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th.

Institutional Investors Weigh In On Haemonetics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP increased its position in shares of Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after buying an additional 363,702 shares during the period. Thrivent Financial for Lutherans lifted its stake in Haemonetics by 14.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock worth $98,716,000 after purchasing an additional 164,111 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Haemonetics by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock valued at $95,986,000 after purchasing an additional 21,547 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Haemonetics by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier’s stock valued at $77,470,000 after purchasing an additional 10,990 shares in the last quarter. Finally, Boston Trust Walden Corp increased its holdings in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

Haemonetics stock opened at $63.03 on Monday. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of 24.81, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics has a 12-month low of $58.80 and a 12-month high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The business’s 50-day simple moving average is $66.05 and its 200 day simple moving average is $74.70.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, research analysts anticipate that Haemonetics will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.